Biocon shares gained 2.8% on the Bombay Stock Exchange (BSE) on Monday, marking an intraday high of ₹375.05 per share. This spike in investor interest followed a major announcement from its subsidiary, Biocon Biologics, which received US FDA approval for YESINTEK (Ustekinumab-kfce), a biosimilar to Stelara. YESINTEK is designed to treat conditions such as Crohn's disease, plaque psoriasis, ulcerative colitis, and psoriatic arthritis.
By 9:27 AM, the Biocon share price had risen 1.32% to ₹369.6 per share, outperforming the broader Sensex, which was up by 0.58%. The company's market capitalisation stood at an impressive ₹44,374.18 crore. With a 52-week high of ₹395.65 and a low of ₹236.8, Biocon has demonstrated robust growth, supported by strategic developments and strong share market investment trends.
A boost from strategic licensing agreements
The FDA approval comes as part of a settlement and licensing agreement with Janssen Biotech, allowing Biocon Biologics to commercialise YESINTEK in the US starting February 2025. This development underscores Biocon's emphasis on innovation and global partnerships, key drivers for enhancing its presence in the competitive biopharmaceutical landscape.
Biocon Biologics has carved a niche in developing cost-effective biosimilars that cater to therapeutic areas such as oncology, immunology, and nephrology. With its state-of-the-art manufacturing facilities and regulatory approvals from bodies like the US FDA and EMA, Biocon Biologics is well-positioned to leverage share market investment momentum.
Biocon's growth in a dynamic market
Biocon's consistent performance highlights its ability to adapt and grow in the ever-evolving share market investment environment. Over the past year, Biocon shares have surged 51.5%, far outpacing the Sensex's 18% growth. This remarkable trajectory is fuelled by its focus on affordable biosimilars and strategic collaborations, making it a preferred choice for investors seeking long-term growth in the share market.
Key takeaways
For android only